
Oncology NEWS International
- Oncology NEWS International Vol 4 No 4
- Volume 4
- Issue 4
Two New Dilaudid Dosage Forms Are Available From Knoll
WHIPPANY, NJ--Two new forms of Dilaudid (hydromorphone HCL)-- Dilaudid 8 mg tablets and Dilaudid-5 Oral Liquid--are now available from Knoll Pharmaceutical Company.
WHIPPANY, NJ--Two new forms of Dilaudid (hydromorphone HCL)--Dilaudid 8 mg tablets and Dilaudid-5 Oral Liquid--are now availablefrom Knoll Pharmaceutical Company.
The 8 mg tablets allow easy titration to a higher hydromorphonedose and are more convenient for patients currently taking twoDilaudid 4 mg tablets per dose, the manufacturer said.
Dilaudid-5 Oral Liquid is designed for patients who have difficultyswallowing solid medications. One teaspoon contains 5 mg of hydromorphoneper 5 mL. The liquid is alcohol-free, colorless, unflavored, andcan be mixed with fruit juice, according to Knoll.
In addition, Knoll is making available a pocket guide "Strategiesfor Cancer Pain Management," written by Ada Rogers, RN, researchassociate and clinical coordinator of the Pain Research Group,Memorial Sloan-Kettering Cancer Center.
The guide contains general information on opioid use in cancerpain, as well as specific dosing information on Dilaudid, includinga dose conversion chart. Call 201-575-5656 (9 am to 5 pm EST)for free copies.
Articles in this issue
almost 31 years ago
First Results of Avicidin Trialsalmost 31 years ago
Chemo Patients Often Develop Menstrual Irregularitiesalmost 31 years ago
Growth Factor Receptor Blockade Moving From Laboratory to Clinicalmost 31 years ago
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigationalmost 31 years ago
Vinorelbine Plus Chemo Promising in Advanced Diseasealmost 31 years ago
Bone Substudy a Part of Tamoxifen Prevention Trialalmost 31 years ago
Ultrasound Breast Screens Useful in Selected Womenalmost 31 years ago
New Roles Forecast for Endocrine Therapyalmost 31 years ago
Antisense Drug Against BCL-2 Effective in Animal Cancer Modelsalmost 31 years ago
Anticancer Drugs From Zeneca in Regulatory Phase of DevelopmentNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































